MedTrace Logo

A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)

NCT01313858 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1613

Last updated 2016-11-01

Study results available
· View outcomes & findings →

Summary

This is a study to assess the use of golimumab (Simponi®) in participants with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The study objective is to evaluate the clinical safety of golimumab (Simponi®) under real-life, clinical practice conditions as assessed by the incidence and type of (serious) adverse events and changes in clinical status of participants as assessed by clinical parameters.

Conditions

  • Arthritis, Rheumatoid
  • Arthritis, Psoriatic
  • Spondylitis, Ankylosing

Interventions

DRUG

Simponi®

DRUG

Methotrexate

Given concomitantly with Simponi®

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2015-09-30
Completion
2015-09-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01313858 on ClinicalTrials.gov